The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

M Warrender-Sparkes; T Spelman; G Izquierdo; M Trojano; A Lugaresi; F Grand'Maison; E Havrdova; D Horakova; C Boz; C Oreja-Guevara; R Alroughani; G Iuliano; P Duquette; M Girard; M Terzi; R Hupperts; P Grammond; T Petersen; R Fernandez-Bolaños; M Fiol; E Pucci; J Lechner-Scott; F Verheul; E Cristiano; V Van Pesch; T Petkovska-Boskova; F Moore; I Kister; R Bergamaschi; ML Saladino; M Slee; M Barnett; MP Amato; C Shaw; N Shuey; C Young; O Gray; L Kappos; H Butzkueven; T Kalincik; V Jokubaitis

Journal article

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

M Warrender-Sparkes, T Spelman, G Izquierdo, M Trojano, A Lugaresi, F Grand'Maison, E Havrdova, D Horakova, C Boz, C Oreja-Guevara, R Alroughani, G Iuliano, P Duquette, M Girard, M Terzi, R Hupperts, P Grammond, T Petersen, R Fernandez-Bolaños, M Fiol Show all

Multiple Sclerosis | SAGE PUBLICATIONS LTD | Published : 2016

DOI: 10.1177/1352458515594041

Download PDF

Abstract

Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). Methods: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. Results: A total of 2640 patients commenced immunomodulatory therapy. Following the intr..

View full abstract

University of Melbourne Researchers

Timothy Spelman Author

Neil Shuey Author

Tomas Kalincik Author

Related Projects (5)

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES

Clinical Centre of Research Excellence in Translational Neuroscience will provide people, pathways and resources to create a novel platform ..

Grants

Awarded by NHMRC

Awarded by Multiple Sclerosis Research Australia Postdoctoral Fellowship

Awarded by National Health and Medical Research Council of Australia

Funding Acknowledgements

The work was supported by the NHMRC Early Career Fellowship [1071124], Multiple Sclerosis Research Australia Postdoctoral Fellowship [11-054], NHMRC Career Development Award [628856], NHMRC Project Grant [1032484], NHMRC Centre for Research Excellence [1001216] and the MSBase Foundation. The MSBase Foundation is a not-for-profit organization that receives support from Merck Serono, Biogen Idec, Novartis Pharma, Bayer Schering, Sanofi-Aventis and BioCSL.